Vanguard Capital Management Acquires 5.26% Passive Stake in Haemonetics Corp (HAE)

Vanguard Capital Management LLC filed a Schedule 13G on April 30, 2026, reporting a new 5.26% stake in Haemonetics Corp (HAE). As of the event date on March 31, 2026, the investment adviser beneficially owns 2,445,817 shares of common stock. The filing indicates that Vanguard holds sole dispositive power over all 2,445,817 shares, while maintaining sole voting power over 355,428 shares. This position represents a significant increase from a previous ownership level of 0.0%, marking a new passive investment threshold for the firm. The filing includes holdings from various Vanguard affiliates, such as Vanguard Global Advisers, LLC and Vanguard Fiduciary Trust Company. Vanguard certified that these securities were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. No other single person's interest in the reported securities exceeds 5% of the total outstanding shares.